Core Insights - Norges Bank increased its stake in Kairong (06821.HK) by purchasing 132,200 shares at an average price of HKD 89.7083 per share, totaling approximately HKD 11.8594 million [1] - Following this transaction, Norges Bank's total shareholding in Kairong rose to 3.3734 million shares, increasing its ownership percentage from 11.75% to 12.24% [1] Summary by Categories - **Transaction Details** - Norges Bank acquired 132,200 shares at an average price of HKD 89.7083 per share [1] - The total investment amounted to approximately HKD 11.8594 million [1] - **Shareholding Changes** - Post-transaction, Norges Bank's total shares held in Kairong reached 3.3734 million [1] - The ownership percentage increased from 11.75% to 12.24% [1]

智通财经APP讯，凯莱英(002821.SZ)发布2025年三季度报告，该公司前三季度营业收入为46.3亿元，同 比增长11.82%。归属于上市公司股东的净利润为8亿元，同比增长12.66%。归属于上市公司股东的扣除 非经常性损益的净利润为7.28亿元，同比增长9.74%。基本每股收益为2.18元。 ...

Core Viewpoint - The company reported a revenue of 4.63 billion RMB for the first three quarters of 2025, reflecting a year-on-year increase of 11.82%, and a net profit attributable to shareholders of 800 million RMB, up 12.66% [1] Revenue Breakdown - The revenue from small molecule business remained stable, while emerging business revenue grew by 71.87% year-on-year, and revenue from large molecule chemistry increased by over 150% [1] - Revenue from large pharmaceutical companies was 2.053 billion RMB, a year-on-year increase of 1.98%, while revenue from small and medium-sized pharmaceutical companies reached 2.577 billion RMB, up 21.14% [1] Future Outlook - The company anticipates that the delivery scale in the fourth quarter will significantly exceed that of the third quarter, projecting an overall revenue growth of 13%-15% for the year [1]

香港联交所最新数据显示，10月27日，Norges Bank增持凯莱英（002821）(06821)13.22万股，每股作价 89.7083港元，总金额约为1185.94万港元。增持后最新持股数目为337.34万股，持股比例为12.24%。 ...

Core Insights - Norges Bank increased its stake in Kairong (06821) by acquiring 132,200 shares at a price of HKD 89.7083 per share, totaling approximately HKD 11.8594 million [1] - Following this acquisition, Norges Bank's total shareholding in Kairong reached 3.3734 million shares, representing a 12.24% ownership stake [1] Company Summary - Norges Bank's recent purchase indicates a strategic move to enhance its investment in Kairong, reflecting confidence in the company's future performance [1] - The increase in shareholding percentage to 12.24% suggests a significant commitment to Kairong, potentially influencing market perception and investor sentiment [1]

格隆汇10月30日丨凯莱英(06821.HK)公布2025年第三季度报告。营收约为人民币14.42亿元，同比下降 0.09%。净利润约为1.83亿元，同比下降13.46%。基本每股收益为0.5元。 前三季度营收约为46.3亿元，同比上升11.82%。净利润约为8亿元，同比上升12.66%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，二零二五年十月三十日 於本公告日期，本公司董事會由董事長兼執行董事 Hao Hong 博士，執行董事楊蕊女士 、張達先生及洪亮先生，非執行董事 Ye Song 博士及張婷女士，以及獨立非執行董事孫 雪嬌博士、侯欣一博士及謝維愷先生組成。 凯莱英医药集团（天津）股份有限公司 2025 年第三季度报告 证券代码：002821 证券简称：凯莱英 公告编 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 二零二五年第三季度報告 本公告乃由凱萊英醫藥集團（天津）股份有限公司（「公司」或「本公司」，連同其附 屬公司統稱「本集團」）根據香港聯合交易所有限公司證券上市規則（「香港上市規 則」）第13.09條及第13.10B條以及證券及期貨條例（香港法例第571章）第XIVA部 項下的內幕消息條文（定義見香港上市規則）而作出。 茲載列本公司在深圳證券交易所網站刊發的《凱萊英醫藥集團（天津）股份有限公 司二零二五年第三季度報告》，僅供參閱。本公司二零二五年第三季度報告（「二 零二五年第三季度報告」）以中、英文雙語編製。如兩個版本有任何不相符之處， 應以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒本公司股東及潛在投資者 ...

Core Insights - The company reported a total revenue of 4.63 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 11.82% [1] - The revenue from emerging businesses increased by 71.87%, while the revenue from large molecule chemistry grew by over 150% [1] - The net profit attributable to shareholders reached 800 million yuan, marking a year-on-year increase of 12.66% [1] Revenue Breakdown - Revenue from large pharmaceutical companies amounted to 2.05 billion yuan, with a year-on-year growth of 1.98% [1] - Revenue from small and medium-sized pharmaceutical companies was 2.58 billion yuan, reflecting a year-on-year increase of 21.14% [1] Profitability Metrics - The overall gross profit margin for the company was 42.44% for the first three quarters of 2025 [1] - The gross profit margin for small molecule business was 46.99%, remaining stable year-on-year [1] - The gross profit margin for emerging businesses improved by 10.57 percentage points to 30.55%, driven by increased delivery scale and capacity utilization [1] Future Outlook - The company anticipates that the delivery scale in the fourth quarter will significantly exceed that of the third quarter [1] - The company expects an annual revenue growth of 13%-15% for the full year [1]

Core Viewpoint - Kailaiying (002821) reported a slight decline in Q3 revenue and net profit, but showed overall growth in the first three quarters of 2025, indicating resilience in emerging and large molecule businesses [1] Financial Performance - Q3 revenue was 1.442 billion yuan, a year-on-year decrease of 0.09% [1] - Q3 net profit was 183 million yuan, a year-on-year decrease of 13.46% [1] - Revenue for the first three quarters reached 4.63 billion yuan, a year-on-year increase of 11.82% [1] - Net profit for the first three quarters was 800 million yuan, a year-on-year increase of 12.66% [1] Business Segments - Revenue from small molecule business remained stable [1] - Revenue from emerging businesses grew by 71.87% year-on-year [1] - Revenue from large molecule business increased by over 150% year-on-year [1] - Revenue from large pharmaceutical companies was 2.053 billion yuan, a year-on-year increase of 1.98% [1] - Revenue from small and medium pharmaceutical companies was 2.577 billion yuan, a year-on-year increase of 21.14% [1] Future Outlook - The order distribution for the second half of the year indicates that Q4 delivery scale will significantly exceed that of Q3 [1] - The company expects annual revenue growth to achieve between 13% and 15% [1]